Pay in 4 interest-free payments of $5.82 Learn more
Ships within 48 hours · Estimated delivery Aug 27 - Sep 1
et al., Altern Ther Health Med (2024) Pilot study on BPC-157 for interstitial cystitis (private clinic) Orthopaedic & Wellness (2023) Peptide Dangers blog highlighting conflicts of interest and unknown risks USADA Spirit of Sport blog (2020): Warning to athletes about BPC-157s unapproved status usada.org
Potential aggregation, impurities and immunogenicity remain unresolved.[4] TB-500 is an N-terminally acetylated seven-amino-acid synthetic fragment of thymosin beta-4 corresponding to residues 172
They have been extensively studied in large randomised controlled trials, with success rates of 60-70% across various causes of ED
Another potential riskthough very unlikelyis vitamin overdose
A 2025 systematic review identified 544 total articles on BPC-157 published between 1993 and 2024, but after applying inclusion criteria, only 36 studies remained eligible for analysis
